RECELL® System Data to be Presented at 44th Annual John A. Boswick Burn & Wound Care Symposium

January 24, 2022

Data presentations highlight broad clinical adoption of the RECELL® System for treatment of burn wounds

VALENCIA, Calif. and MELBOURNE, Australia, Jan. 24, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that six abstracts highlighting the clinical benefits of the RECELL® Autologous Cell Harvesting Device (RECELL® System) have been accepted at the 44th Annual John A. Boswick Burn & Wound Care Symposium. The international conference will be held in Maui, Hawaii, January 22-27, and covers the latest advancements in burn care, wound healing, and infection control.

"The physician-initiated research being presented at this year's Boswick Symposium underscores how the RECELL® System is advancing treatment of burn wounds, both as a monotherapy and in combination with complementary technologies," said Dr. Mike Perry, Chief Executive Officer of AVITA Medical. "With completion of enrollment in both our vitiligo and soft tissue reconstruction pivotal clinical trials, we look forward to progressing our pipeline and simultaneously beginning to realize the immense potential of this innovative technology platform benefitting a broad array of patients with skin defects or wounds."

RECELL® System Abstracts

- Autologous keratinocyte suspension in conjunction with fibrin sealant for the treatment of partial thickness burns. Author: E. Brown, Texas Tech University HSC School of Medicine, Lubbock, TX
- Utilizing glabrous skin from the palm to source autologous regenerative epidermal suspension for deep partial thickness palmar burns. Author: P. Fidler, Burn and Reconstructive Centers of America
- A Retrospective Review of Clinical Outcomes in Superficial and Deep Second-Degree Burn Patients treated with Autologous Skin Cell Suspension (RECELL) and Split Thickness Skin Graft. Author: K. Henry, Jacobi Medical Center, Bronx, New York
- Simplifying the Treatment Algorithm by Reducing Number of Autografting Procedures: Use of ASCS for Thermal Burn Injuries. Author: W. Hickerson, AVITA Medical Consultant
- The holy grail? Experience with autologous skin cell suspension combined with a poly-lactic acid dressing. Author: A. Khandelwal, MD, FACS, FICS, Akron Children's Hospital, Akron, OH
- Biodegradable Temporizing Matrix and Autologous Skin Cell Suspension in Necrotizing Soft Tissue Infection: A Case Report. Author: A. Raghuram, Texas Tech University HSC School of Medicine, Lubbock, TX

For more information about the RECELL System, please visit www.avitamedical.com.

ABOUT AVITA MEDICAL, INC.
AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical's patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient's own skin. The medical devices work by preparing a RES® REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patient's skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Medical's first U.S. product, the RECELL® System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns. The RECELL System is used to prepare Spray-On Skin™ Cells using a small amount of a patient's own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 10,000 patients globally reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL® Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings, and precautions.

In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds, and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe. To learn more, visit www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "intend," "could," "may," "will," "believe," "estimate," "look forward," "forecast," "goal," "target," "project," "continue," "outlook," "guidance," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this press release include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the company's control. Investors should not place considerable reliance on the forward-looking statements contained in this press release. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

This press release was authorized by the review committee of AVITA Medical, Inc.

FOR FURTHER INFORMATION:

U.S. Media Sam Brown, Inc. Christy Curran Phone +1-615-414-8668 christycurran@sambrown.com **O.U.S. Media** Rudi Michelson Phone +61 (0)3 9620 3333 Mobile +61 (0)411 402 737 rudim@monsoon.com.au	**Investors** ICR Westwicke Caroline Corner Phone +1-415-202-5678 caroline.corner@westwicke.com